Servier To Tackle Parkinson's With Oncodesign Pact

13 Mar 2019

A couple of years after Ipsen returned the rights to an LRRK2 Parkinson's program, Oncodesign has bagged a new partner in Servier and stands to bank up to €320m if all goes well.

Servier SA and fellow French firm Oncodesign SA have linked up to develop new therapies for Parkinson's disease and are going after one of the key targets linked to treating the neurodegenerative disorder – the inhibition of the LRRK2 kinase in the brain.

The partnership is based on the leucine-rich repeat kinase 2 (LRRK2) inhibitors derived from Oncodesign's proprietary Nanocyclix platform. The project...